The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
A pentadentate aromatic metallotexaphyrin with photosensitizing
properties. Motexafin lutetium preferentially accumulates in tumor
cells due to their increased rates of metabolism and absorbs light,
forming an extended high energy conformational state that produces high
quantum yields of singlet oxygen, resulting in local cytotoxic effects.